CY1121783T1 - Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου - Google Patents
Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινουInfo
- Publication number
- CY1121783T1 CY1121783T1 CY20191100523T CY191100523T CY1121783T1 CY 1121783 T1 CY1121783 T1 CY 1121783T1 CY 20191100523 T CY20191100523 T CY 20191100523T CY 191100523 T CY191100523 T CY 191100523T CY 1121783 T1 CY1121783 T1 CY 1121783T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- drug conjugate
- treatment
- igf
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 3
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical class CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ένα σύζευγμα αντισώματος-φαρμάκου δυνάμενο δέσμευσης IGF-1R. Από μια άποψη του θέματος, η εφεύρεση σχετίζεται με ένα σύζευγμα αντισώματος-φαρμάκου περιλαμβάνοντας ένα αντίσωμα δυνάμενο δέσμευσης σε IGF-1R, με το εν λόγω αντίσωμα να συζεύγεται σε τουλάχιστον ένα φάρμακο που επιλέγεται από παράγωγα δολαστατίνης 10 και αουριστατινών. Η εφεύρεση περιλαμβάνει επίσης μέθοδο αγωγής και τη χρήση του εν λόγω συζεύγματος αντισώματος-φαρμάκου για την αγωγή του καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305620 | 2014-04-25 | ||
PCT/EP2015/059045 WO2015162291A1 (en) | 2014-04-25 | 2015-04-27 | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121783T1 true CY1121783T1 (el) | 2020-07-31 |
Family
ID=50630736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100523T CY1121783T1 (el) | 2014-04-25 | 2019-05-15 | Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου |
Country Status (27)
Country | Link |
---|---|
US (2) | US10633448B2 (el) |
EP (2) | EP3134124B1 (el) |
JP (1) | JP6258523B2 (el) |
KR (1) | KR101795984B1 (el) |
CN (1) | CN106456800B (el) |
AU (1) | AU2015250759B2 (el) |
BR (1) | BR112016024619A2 (el) |
CA (1) | CA2946469C (el) |
CY (1) | CY1121783T1 (el) |
DK (1) | DK3134124T3 (el) |
ES (1) | ES2727103T3 (el) |
HR (1) | HRP20190888T8 (el) |
HU (1) | HUE044862T2 (el) |
IL (1) | IL248455B (el) |
LT (1) | LT3134124T (el) |
MA (2) | MA47811A (el) |
MX (1) | MX2016013704A (el) |
MY (1) | MY186711A (el) |
PL (1) | PL3134124T3 (el) |
PT (1) | PT3134124T (el) |
RS (1) | RS58742B1 (el) |
RU (1) | RU2692563C2 (el) |
SA (1) | SA516380120B1 (el) |
SI (1) | SI3134124T1 (el) |
TN (1) | TN2016000472A1 (el) |
UA (1) | UA120364C2 (el) |
WO (1) | WO2015162291A1 (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3134124T3 (da) * | 2014-04-25 | 2019-05-06 | Pf Medicament | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft |
JP6968790B2 (ja) | 2015-10-26 | 2021-11-17 | ピエール、ファーブル、メディカマン | Igf−1r発現癌の処置のための組成物 |
US11340233B2 (en) | 2016-03-07 | 2022-05-24 | Pierre Fabre Medicament | Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
MX2021003295A (es) | 2018-09-27 | 2021-07-16 | Pf Medicament | Enlazadores basados en sulfomaleimida y sus correspondientes conjugados. |
CN111327570B (zh) | 2018-12-14 | 2021-09-17 | 北京京东尚科信息技术有限公司 | 验证方法、装置和计算机可读存储介质 |
EP3735991A1 (fr) * | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2023240223A2 (en) * | 2022-06-10 | 2023-12-14 | Acelyrin, Inc. | Anti-igf-1r antibody compositions |
EP4353220A1 (en) | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
WO2024180233A1 (en) | 2023-03-02 | 2024-09-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | A therapeutic hpv vaccine based on validated target epitopes |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5767237A (en) | 1993-10-01 | 1998-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Peptide derivatives |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
EP2286844A3 (en) * | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
AR065803A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
WO2008141044A2 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
WO2009126934A2 (en) | 2008-04-11 | 2009-10-15 | Seattle Genetics, Inc. | Detection and tratment of pancreatic, ovarian and other cancers |
AU2010229192A1 (en) | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
US20100316639A1 (en) * | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
ES2528956T3 (es) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | Nuevos derivados de auristatina y su uso |
CN103379912B (zh) | 2010-09-29 | 2016-03-16 | 西雅图基因公司 | 正羧烷基耳他汀及其应用 |
US9272052B2 (en) * | 2010-10-22 | 2016-03-01 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
JP6105477B2 (ja) | 2010-11-05 | 2017-03-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 |
ES2543888T3 (es) | 2011-03-16 | 2015-08-25 | Seattle Genetics, Inc. | N-carboxialquil-auristatinas y su utilización |
US9150644B2 (en) * | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
BR112013030372A2 (pt) | 2011-05-27 | 2016-08-30 | Ambrx Inc | composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US10800856B2 (en) | 2012-06-07 | 2020-10-13 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
EP4406612A3 (en) | 2012-06-19 | 2024-10-16 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
AU2013302273A1 (en) | 2012-08-14 | 2015-02-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
WO2014096551A1 (en) | 2012-12-21 | 2014-06-26 | Glykos Finland Oy | Linker-payload molecule conjugates |
FR3005051A1 (fr) | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
DK3134124T3 (da) * | 2014-04-25 | 2019-05-06 | Pf Medicament | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft |
SI3134125T1 (sl) * | 2014-04-25 | 2020-02-28 | Pierre Fabre Medicament | Konjugat zdravila s protitelesom in uporaba le-tega za zdravljenje raka |
MA39378B2 (fr) * | 2014-04-25 | 2021-02-26 | Pf Medicament | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer |
JP6968790B2 (ja) * | 2015-10-26 | 2021-11-17 | ピエール、ファーブル、メディカマン | Igf−1r発現癌の処置のための組成物 |
-
2015
- 2015-04-27 DK DK15720045.2T patent/DK3134124T3/da active
- 2015-04-27 AU AU2015250759A patent/AU2015250759B2/en not_active Ceased
- 2015-04-27 SI SI201530751T patent/SI3134124T1/sl unknown
- 2015-04-27 EP EP15720045.2A patent/EP3134124B1/en active Active
- 2015-04-27 PT PT15720045T patent/PT3134124T/pt unknown
- 2015-04-27 WO PCT/EP2015/059045 patent/WO2015162291A1/en active Application Filing
- 2015-04-27 CA CA2946469A patent/CA2946469C/en active Active
- 2015-04-27 US US15/306,351 patent/US10633448B2/en active Active
- 2015-04-27 MA MA047811A patent/MA47811A/fr unknown
- 2015-04-27 TN TN2016000472A patent/TN2016000472A1/en unknown
- 2015-04-27 RU RU2016145444A patent/RU2692563C2/ru active
- 2015-04-27 RS RS20190615A patent/RS58742B1/sr unknown
- 2015-04-27 JP JP2016564149A patent/JP6258523B2/ja active Active
- 2015-04-27 UA UAA201611833A patent/UA120364C2/uk unknown
- 2015-04-27 KR KR1020167031683A patent/KR101795984B1/ko active IP Right Grant
- 2015-04-27 ES ES15720045T patent/ES2727103T3/es active Active
- 2015-04-27 PL PL15720045T patent/PL3134124T3/pl unknown
- 2015-04-27 MX MX2016013704A patent/MX2016013704A/es active IP Right Grant
- 2015-04-27 EP EP19154902.1A patent/EP3498301A1/en not_active Withdrawn
- 2015-04-27 CN CN201580033382.0A patent/CN106456800B/zh active Active
- 2015-04-27 HU HUE15720045 patent/HUE044862T2/hu unknown
- 2015-04-27 MY MYPI2016703874A patent/MY186711A/en unknown
- 2015-04-27 MA MA39909A patent/MA39909B1/fr unknown
- 2015-04-27 BR BR112016024619A patent/BR112016024619A2/pt not_active Application Discontinuation
- 2015-04-27 LT LTEP15720045.2T patent/LT3134124T/lt unknown
-
2016
- 2016-10-23 IL IL248455A patent/IL248455B/en active IP Right Grant
- 2016-10-23 SA SA516380120A patent/SA516380120B1/ar unknown
-
2019
- 2019-05-15 HR HRP20190888TT patent/HRP20190888T8/hr unknown
- 2019-05-15 CY CY20191100523T patent/CY1121783T1/el unknown
-
2020
- 2020-02-26 US US16/801,491 patent/US11661457B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122472T1 (el) | Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου | |
CY1121783T1 (el) | Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου | |
CY1121949T1 (el) | Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου | |
CY1125440T1 (el) | Αντι-τιμ-3 αντισωματα και συνθεσεις | |
CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
CY1123858T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CO2018005433A2 (es) | Conjugados de fármaco de anticuerpo her2 específicos de sitio | |
MX2021007620A (es) | Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1). | |
CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
CU20170169A7 (es) | Anticuerpos de factor xi | |
MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
BR112016024525A2 (pt) | novos anticorpos anti-rnf43 e métodos de uso | |
GT201700102A (es) | Conjugados de anticuerpo-fármaco | |
EA201900562A1 (ru) | Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
MX2020006010A (es) | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. | |
DK3870234T3 (da) | Antistoflægemiddelkonjugater omfattende ecteinascidinderivater | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
CY1124183T1 (el) | Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης |